ZNF217 is overexpressed and enhances cell migration and invasion in colorectal carcinoma

Asian Pacific Journal of Cancer Prevention

Volumn 16, Issue 6, 2015, Pages 2459-2463

  Zhang, Zi Chao ^a   Zheng, Li Qiang ^b   Pan, Li Jie ^a   Guo, Jin Xing ^a   Yang, Guo Shan ^a  

^a FIRST HOSPITAL OF TSINGHUA UNIVERSITY   (China)

^b CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Colorectal carcinoma; Expression; Invasion; Migration; ZNF217

Indexed keywords

MESSENGER RNA; TRANSACTIVATOR PROTEIN; TUMOR MARKER; ZNF217 PROTEIN, HUMAN;

ADULT; AGED; APOPTOSIS; CANCER GRADING; CANCER STAGING; CELL ADHESION; CELL CULTURE; CELL MOTION; CELL PROLIFERATION; COLON; COLORECTAL TUMOR; COMPARATIVE STUDY; ENZYME IMMUNOASSAY; FEMALE; FOLLOW UP; GENETICS; HUMAN; LYMPH NODE METASTASIS; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; RECTUM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; TUMOR INVASION; WESTERN BLOTTING;

ADULT; AGED; APOPTOSIS; BIOMARKERS, TUMOR; BLOTTING, WESTERN; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; COLON; COLORECTAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RECTUM; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TRANS-ACTIVATORS;

EID: 84929165005     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2015.16.6.2459     Document Type: Article

References (21)

1. Bai WD, Ye XM, Zhang MY, Zhu HY, et al (2014). MiR-200c suppresses TGF-β signaling and counteracts trastuzumab resistance and metastasis by targeting ZNF217 and ZEB1 in breast cancer. Int J Cancer, 6, 1356-68.
2. Bozkurt O, Inanc M, Turkmen E, et al (2014). Clinicopathological characteristics and prognosis of patients according to recurrence time after curative resection for colorectal cancer. Asian Pac J Cancer Prev, 21, 9277-81.
3. Frietze S, O'Geen H, Littlepage LE, et al (2014). Global analysis of ZNF217 chromatin occupancy in the breast cancer cell genome reveals an association with ER alpha. BMC Genomics, 15, 520.
4. Geppert CI, Rummele P, Sarbia M, et al (2014). Multi-colour FISH in oesophageal adenocarcinoma-predictors of prognosis independent of stage and grade. Br J Cancer, 12, 2985-95.
5. Han K, Jin J, Maia M, et al (2014). Lower exposure and faster clearance of bevacizumab in gastric cancer and the impact of patient variables: analysis of individual data from AVAGAST phase III trial. AAPSJ, 5, 1056-63.
6. Hidaka S, Yasutake T, Takeshita H, et al (2000). Differences in 20q13.2 copy number between colorectal cancers with and without liver metastasis. Clin Cancer Res, 7, 2712-7.
7. Holzmann K, Kohlhammer H, Schwaenen C, et al (2004). Genomic DNA-chip hybridization reveals a higher incidence of genomic amplifications in pancreatic cancer than conventional comparative genomic hybridization and leads to the identification of novel candidate genes. Cancer Res, 13, 4428-33.
8. Huang HN, Lin MC, Huang WC, et al (2014). Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations and ZNF217 amplification in ovarian clear cell carcinoma. Mod Pathol, 7, 983-90.
9. Kumaravel TS, Bristow RG (2005). Detection of genetic instability at HER-2/neu and p53 loci in breast cancer cells sing Comet-FISH. Breast Cancer Res Treat, 1, 89-93.
10. Letessier A, Sircoulomb F, Ginestier C, et al (2006). Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers. BMC Cancer, 6, 245.
11. Li C, Yang W, Zhang J, et al (2014). SREBP-1 has a prognostic role and contributes to invasion and metastasis in human hepatocellular carcinoma. Int J Mol Sci, 5, 7124-38.
12. Littlepage LE, Adler AS, Kouros-Mehr H, et al (2012). The transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progression. Cancer Discov, 7, 638-51.
13. Mahmoud AS, Umair A, Azzeghaiby SN, et al (2014). Expression of cyclooxygenase-2 (COX-2) in colorectal adenocarcinoma: an immunohistochemical and histopathological study. Asian Pac J Cancer Prev, 16, 6787-90.
14. Mao XG, Yan M, Xue XY, et al (2011). Overexpression of ZNF217 in glioblastoma contributes to the maintenance of glioma stem cells regulated by hypoxia-inducible factors. Lab Invest, 7, 1068-78.
15. Rahman MT, Nakayama K, Rahman M, et al (2012). Prognostic and therapeutic impact of the chromosome 20q13.2 ZNF217 locus amplification in ovarian clear cell carcinoma. Cancer, 11, 2846-57.
16. Thillainadesan G, Chitilian JM, Isovic M, et al (2012). TGF-β-dependent active demethylation and expression of the p15ink4b tumor suppressor are impaired by the ZNF217/CoREST complex. Mol Cell, 5, 636-49.
17. Thollet A, Vendrell JA, Payen L, et al (2010). ZNF217 confers resistance to the pro-apoptotic signals of paclitaxel and aberrant expression ofAurora-A in breast cancer cells. Mol Cancer, 9, 291.
18. Vendrell JA, Thollet A, Nguyen NT, et al (2012). ZNF217 is a marker of poor prognosis in breast cancer that drives epithelial-mesenchymal transition and invasion. Cancer Res, 14, 3593-606.
19. Wang WS, Yu SL, Yang XS, et al (2013). Expression and significance of twist and E-cadherin in ovarian cancer tissues. Asian Pac J Cancer Prev, 2, 669-72.
20. Zeng H, Zheng R, Guo Y, et al (2014). Cancer survival in China, 2003-2005: A population-based study. Int J Cancer. [Epub ahead of print].
21. Zhang X, Xu J, Liu H, et al (2014). Predictive biomarkers for the efficacy of cetuximab combined with cisplatin and capecitabine in advanced gastric or esophagogastric junction adenocarcinoma: a prospective multicenter phase 2 trial. Med Oncol, 10, 226.